Urinary bladder cancer is a worldwide health issue and the ninth most prevalent cancer across the globe, accounting for almost two-thirds of all urinary malignancies. Interleukin 17 (IL17) is a pro-inflammatory cytokine with pivotal modulatory effects on antitumor immune responses and has been reported to play a prominent role in the occurrence and development of bladder cancer. The present study aimed to measure the quantitative serum and urine levels of IL-17 in patients with bladder cancer. Blood and urine samples were obtained from 50 diagnosed bladder cancers and 96 healthy people as a control group. The serum and urine level of IL-17 was evaluated using an enzyme-linked immunosorbent assay. It has been revealed that the level of IL-17 was higher in all patients, as compared to that in controls. These results indicated that this interleukin is an indicator to predict the progression or recurrence of the disease.
Floyd RA, Kotake Y, Towner RA, GUO W-X, NAKAE D, KONISHI Y. Cancer Facts and Figures American Cancer Society.2004.
Huang CC, Wang CH, Fu CH, Huang CC, Chang PH, Chen YW, et al. Association between cigarette smoking and interleukin-17A expression in nasal tissues of patients with chronic rhinosinusitis and asthma. Medicine. 2016;95(47):e5432.
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74-108.
AlObaidi SA, AlSaimary IE, ALMusafer MM. Immunological Estimation of Inflammatory Interleukins (IL-4, IL-6 & IL-10) Among Patients with Bladder Cancer. Clin Med Health Res J. 2021;1(3):57-68.
Aslani A, Haghshenas MR, Erfani N, Khezri AA. IL17A and IL17F genetic variations in iranian patients with urothelial bladder cancer: a case-control study. Middle East J Cancer. 2021;12(3):377-82.
Chen L-H, Shan K-S, Wu P-L, Yan Z-W, Wang W. Alteration of IFN-γ, IL-4, IL-17 and TGF-β levels in serum of patients with chronic lymphocytic leukemia treated with FCR. Zhongguo shi yan xue ye xue za zhi. 2017;25(6):1615-20.
Fattahi S, Karimi M, Ghatreh-Samani M, Taheri F, Shirzad H, Mohammad Alibeigi F, et al. Correlation between aryl hydrocarbon receptor and IL-17(+) and Foxp3(+) T-cell infiltration in bladder cancer. Int J Exp Pathol. 2021;102(6):249-59.
Mahdi NK, Ghdbhan AF, Saleh MM. Pro-inflammatory Cytokines for Evaluation of the Diagnostic Performance for the Urinary Bladder Cancer. Asian J Cancer. 2013;12(3):169-73.
Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM, et al. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol. 2017;71(3):447-61.
Apolo AB, Grossman HB, Bajorin D, Steinberg G, Kamat AM. Practical use of perioperative chemotherapy for muscle-invasive bladder cancer: summary of session at the Society of Urologic Oncology annual meeting. Urol Oncol. 2012;30(6):772-80.
Baharlou R, Ahmadi Vasmehjani A, Dehghani A, Ghobadifar MA, Khoubyari M. Reduced interleukin-17 and transforming growth factor Beta levels in peripheral blood as indicators for following the course of bladder cancer. Immune Netw. 2014;14(3):156-63.
Song Y, Yang JM. Role of interleukin (IL)-17 and T-helper (Th)17 cells in cancer. Biochem Biophys Res Commun. 2017;493(1):1-8.
Asadzadeh Z, Mohammadi H, Safarzadeh E, Hemmatzadeh M, Mahdian-Shakib A, Jadidi-Niaragh F, et al. The paradox of Th17 cell functions in tumor immunity. Cell Immunol. 2017;322:15-25.
Xue J, Wang Y, Chen C, Zhu X, Zhu H, Hu Y. Effects of Th17 cells and IL-17 in the progression of cervical carcinogenesis with high-risk human papillomavirus infection. Cancer Med. 2018;7(2):297-306.
Yang B, Kang H, Fung A, Zhao H, Wang T, Ma D. The role of interleukin 17 in tumour proliferation, angiogenesis, and metastasis. Mediators Inflamm. 2014;2014:623759.
De Angulo A, Faris R, Daniel B, Jolly C, deGraffenried L. Age-related increase in IL-17 activates pro-inflammatory signaling in prostate cells. Prostate. 2015;75(5):449-62.
Song Y, Yang M, Zhang H, Sun Y, Tao Y, Li H, et al. IL-17 affects the progression, metastasis, and recurrence of laryngeal cancer via the inhibition of apoptosis through activation of the PI3K/AKT/FAS/FASL pathways. Journal of Immunology Research. 2020;2020.
Mousa, F. A., Jasim, H. A., & Shakir, F. (2022). A Prognostic Impact of Interleukin 17 (IL-17) as an Immune-Marker in Patients with Bladder Cancer. Archives of Razi Institute, 77(3), 1059-1065. doi: 10.22092/ari.2022.357801.2098
F. A Mousa; H. A Jasim; F Shakir. "A Prognostic Impact of Interleukin 17 (IL-17) as an Immune-Marker in Patients with Bladder Cancer". Archives of Razi Institute, 77, 3, 2022, 1059-1065. doi: 10.22092/ari.2022.357801.2098
Mousa, F. A., Jasim, H. A., Shakir, F. (2022). 'A Prognostic Impact of Interleukin 17 (IL-17) as an Immune-Marker in Patients with Bladder Cancer', Archives of Razi Institute, 77(3), pp. 1059-1065. doi: 10.22092/ari.2022.357801.2098
Mousa, F. A., Jasim, H. A., Shakir, F. A Prognostic Impact of Interleukin 17 (IL-17) as an Immune-Marker in Patients with Bladder Cancer. Archives of Razi Institute, 2022; 77(3): 1059-1065. doi: 10.22092/ari.2022.357801.2098